CN105596690A - Pharmaceutical composition for treating chronic tonsillitis - Google Patents

Pharmaceutical composition for treating chronic tonsillitis Download PDF

Info

Publication number
CN105596690A
CN105596690A CN201610038270.0A CN201610038270A CN105596690A CN 105596690 A CN105596690 A CN 105596690A CN 201610038270 A CN201610038270 A CN 201610038270A CN 105596690 A CN105596690 A CN 105596690A
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
group
chronic tonsillitis
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610038270.0A
Other languages
Chinese (zh)
Inventor
王传秀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Yuntian Biotechnology Co Ltd
Original Assignee
Qingdao Yuntian Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Yuntian Biotechnology Co Ltd filed Critical Qingdao Yuntian Biotechnology Co Ltd
Priority to CN201610038270.0A priority Critical patent/CN105596690A/en
Publication of CN105596690A publication Critical patent/CN105596690A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A61K36/195—Strobilanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315—Isatis, e.g. Dyer's woad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538—Schizonepeta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/78—Saururaceae (Lizard's-tail family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A61K36/855—Clerodendrum, e.g. glorybower
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/89—Cyperaceae (Sedge family)
    • A61K36/8905—Cyperus (flatsedge)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to the field of medicine, and relates to a pharmaceutical composition for treating chronic tonsillitis, in order to overcome shortcomings in the prior art as well as relieve pain of patients with chronic tonsillitis. The pharmaceutical composition is prepared from, by weight, 10-12 parts of Bupleurum Chinense, 5-8 parts of Herba Schizonepetae, 6-9 parts of Radix Rehmanniae Preparata , 3-5 parts of Folium Isatidis, 10-12 parts of Herba Menthae , 10-12 parts of Rhizoma Chuanxiong, 3-5 parts of Flos Carthami, 3-5 parts of Herba Houttuyniae, 10-12 parts of Radix Astragali, 8-10 parts of Rhizoma Cyperi, 6-9 parts of Fructus Arctii, 10-12 parts of Folium Ginkgo, 10-12 parts of Mahonia Fortunei, 10-12 parts of Tribulus Terrestris, 12-15 parts of Cochinchnese Asparagus Root and 9-12 parts of Radix Glycyrrhizae. The pharmaceutical composition has significant anti-inflammatory analgesic activities, is remarkable in curative effect, safe and reliable, and has broad clinical application prospect.

Description

A kind of pharmaceutical composition for the treatment of chronic tonsillitis
Technical field
The invention belongs to field of medicaments, relate to a kind of pharmaceutical composition and medical usage thereof for the treatment of chronic tonsillitis.
Background technology
Chronic tonsillitis many by acute tonsillitis repeatedly show effect transfer to chronic. Suffer from acute infectious disease (as scarlet fever, measles,Influenza, diphtheria etc.) after can cause chronic tonsillitis, nasal cavity has sinus infection this disease that also can occur together. Pathogen is with streptococcusAnd staphylococcus etc. is the most common. Clinical manifestation is frequent pharyngeal discomfort, and foreign body sensation is dry, itch, irritable cough, halitosisEtc. symptom. They are many causes because bacterium and secretion lodge in tonsillar pit. Autoallergy may be also the cause of disease. It facesBed shows as: 1. the pharyngalgia of repeatedly showing effect: catch a cold whenever, suffer from cold, tired, not good enough or tobacco and wine of sleeping stimulate after pharyngalgia outbreak,And there is pharyngeal discomfort and stop up sense. 2. halitosis: because the breeding of almond Endophytic bacteria is grown and residues in intratonsillar purulence boltPlug thing, often can cause halitosis. 3. antiadoncus: be more common in children, loose tonsillotome can make dysphagia, speaks ambiguousClearly, unsmooth breath or when sleep snoring. 4. whole body performance: intratonsillar bacterium, purulent core often enters alimentary canal with swallowing, fromAnd the indigestion of arching. As bacteriotoxin enters in body, can there be headache, limbs fatigue, the easily performance such as fatigue or low-heat.
At present, the chronic tonsillitis Western medicine for the treatment of is a lot, but most drug result for the treatment of is poor, and treat in addition high,The shortcomings such as side effect is large, even affect patient health when serious. In addition, also have the Chinese medicine of a lot for the treatment of chronic tonsillitis,But the shortcomings such as great majority have that result for the treatment of is poor, cure rate is low and treatment cycle is long.
Summary of the invention
In order to make up the deficiencies in the prior art, alleviate the misery of chronic tonsillitis, the invention provides one and treat slowlyIt is evident in efficacy, safe and reliable for the tonsillitic pharmaceutical composition of property, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
Treat a pharmaceutical composition for chronic tonsillitis, this pharmaceutical composition is made up of the raw material of following weight portion: northern bavin10-12 part, schizonepeta 5-8 part, cultivated land 6-9 part, folium isatidis 3-5 part, peppermint 10-12 part, Ligusticum wallichii 10-12 part, red recklesslyFlower 3-5 part, cordate houttuynia 3-5 part, Radix Astragali 10-12 part, rhizoma cyperi 8-10 part, great burdock achene 6-9 part, ginkgo leaf 10-12 part,Chinese mahonia 10-12 part, tribulus terrestris 10-12 part, lucid asparagus 12-15 part, Radix Glycyrrhizae 9-12 part.
In pharmaceutical composition described above, various traditional Chinese medicinal components are all got its conventional agents area and are used as medicine. According to it to chronic flatThe result for the treatment of of peach body inflammation, described pharmaceutical composition is made up of the raw material of following weight portion: 11 parts of Bupleurum Chineses, 7 parts of schizonepeta,7 parts, cultivated land, 4 parts of folium isatidis, 11 parts of peppermints, 11 parts of Ligusticum wallichiis, 4 parts, safflower, 4 parts of cordate houttuynias, 11 parts of the Radixs Astragali, perfume (or spice)Attached 9 parts, 8 parts of great burdock achenes, 11 parts of ginkgo leaves, 11 parts of Chinese mahonias, 11 parts of tribulus terrestrises, 13 parts of lucid asparagus, Radix Glycyrrhizae10 parts.
In pharmaceutical composition described above, can also contain Poria cocos 5-8 part and Radix Angelicae Sinensis 12-15 part. This in two Chinese medicine can enterOne step strengthens the anti-inflammatory pain-stopping effect of aforementioned pharmaceutical compositions of the present invention.
The present invention also asks to protect the purposes of aforementioned pharmaceutical compositions in preparation treatment chronic tonsillitis medicine. Medicine of the present inventionCompositions, in the time for the treatment of chronic tonsillitis, demonstrates remarkable anti-inflammatory and antalgic activity. Drug effect embodiment 7 of the present invention shows,Give positive drug and pharmaceutical composition of the present invention and all can obtain significant antiphlogistic effects, wherein drug regimen object height of the present invention agentThe antiphlogistic effects of amount group and positive controls have utmost point significant difference, and pharmaceutical composition low dose group and positive controls have aobviousWork property difference, it is positive right that this shows that the high dose group of pharmaceutical composition of the present invention and the antiphlogistic effects of low dose group will significantly be better thanAccording to group. Drug effect embodiment 8 mouse of the present invention lick foot response latency time showing, with model group comparison, and 1h and 2h after administrationAfter, be all greater than model group the incubation period that the mouse of each administration group of pharmaceutical composition of the present invention is added foot reaction, exists dosage to rely onRelation, and be significantly greater than model group (P < 0.05) incubation period of high dose group. Illustrate that this pharmaceutical composition of the present invention can prolongWhat long mouse stimulated hot plate adds the sufficient response latency, has certain analgesic activity. Under same experiment condition, positive control drugDobell group (P < 0.05) and folium isatidis supernatant sheet group (1h, P < 0.05; 2h, P < 0.01) also having extended mouse, to add foot anti-In the incubation period of answering, have certain analgesic activity, but its analgesic effect and model group there was no significant difference.
In order to express better pharmaceutical composition of the present invention, pharmaceutical composition of the present invention can be prepared into clinically conventionalFormulation. Such as, powderous preparations, powder, pill, sublimed preparation, paste, granule, oral liquid, syrup, tablet, capsuleThe preparations such as agent, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, pharmaceutical composition of the present invention is prepared into powder, mixture, tablet or capsule according to conventional preparation technology.
The present invention also provides a kind of preparation method of pharmaceutical composition described above, and it mainly comprises following step: get prescriptionMeasure above-mentioned Chinese medicine and be broken into meal, adding volumetric concentration according to 4～9 times of meal gross weight is 40%～95% ethanolic solution,Refluxing extraction three times, return time is 2～5h, filters, filtrate recycling ethanol, cold filtration, washes with water, dry rearObtain Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method,As tablet, capsule etc.
The present invention is inventor through research repeatedly, progressively improves, and last successful a kind of curative effect is the chronic almond for the treatment of preferablyThe medicine of body inflammation, for showing the result for the treatment of of medicine of the present invention to chronic tonsillitis, the present invention takes this medicine to 180 examplesThe patient of chronic tonsillitis carried out clinical observation, and select chronic tonsillitis 179 examples with comparativity to doFor control group. Treatment group patient takes medicine twice of the present invention every day, sooner or later respectively once, once takes 5 grams of medicines, contrastGroup patient takes the oral drugs of conventional therapy chronic tonsillitis. Treat after one month, treatment results is in table 1.
Table 1 treatment group and the treatment of control group result table of comparisons
Cure Effectively Cure rate Efficient
Treatment group 141 examples 165 examples 78.33％ 91.67％
Control group 93 examples 117 examples 51.96％ 65.36％
Treatment group is compared control group and is had higher cure rate and efficient, thinks thus, and medicine of the present invention is treated chronic almondBody inflammation has good effect, and observes through the treatment of month, takes medicine of the present invention and does not occur the secondary work of any poisonWith.
Pharmaceutical composition of the present invention merges aspect tinnitus in treatment, compared with prior art has following advantage:
1) compared with the chemotherapeutic agent of current treatment, pharmaceutical composition of the present invention is natural pure Chinese medicinal preparation, bad reactionSignificantly reduce with side effect, and pharmaceutical composition effect of the present invention is comprehensive, medication effect is better, and has improved patient'sQuality of life.
2) in pharmaceutical composition of the present invention, contain multi-medicament component, action target spot is numerous, pharmacological evaluation show itself and existingMedicine has significant synergy aspect anti-inflammatory and antalgic, and can significantly reduce chronic tonsillitis and go outExisting tinnitus symptom, improves patient's acceptance and compliance.
Detailed description of the invention
Further describe the present invention by specific embodiment below, but those skilled in the art should know, described embodiment alsoDo not limit the present invention in any way.
(1) example of formulations part
Embodiment 1 pharmaceutical composition of the present invention and preparation technology
The weight portion of traditional Chinese medicinal components: 10 parts of Bupleurum Chineses, 5 parts of schizonepeta, 6 parts, cultivated land, 3 parts of folium isatidis, 10 parts of peppermints,10 parts of Ligusticum wallichiis, 3 parts, safflower, 3 parts of cordate houttuynias, 10 parts of the Radixs Astragali, 8 parts of rhizoma cyperis, 6 parts of great burdock achenes, 10 parts of ginkgo leaves,10 parts of Chinese mahonias, 10 parts of tribulus terrestrises, 12 parts of lucid asparagus, 9 parts, Radix Glycyrrhizae.
Get the above-mentioned Chinese medicine of recipe quantity and be broken into meal, adding volumetric concentration according to 4～9 times of meal gross weight is 40%～95%Ethanolic solution, refluxing extraction three times, return time is 2～5h, filter, filtrate recycling ethanol, cold filtration, washes with waterWash, after being dried, obtain Chinese medical concrete; Those skilled in the art can this preparation method technical prepare clinically conventional inMedicine pharmaceutical dosage form, as tablet, capsule etc.
Embodiment 2 pharmaceutical composition of the present invention and preparation technology
The weight portion of traditional Chinese medicinal components: 12 parts of Bupleurum Chineses, 8 parts of schizonepeta, 9 parts, cultivated land, 5 parts of folium isatidis, 12 parts of peppermints,12 parts of Ligusticum wallichiis, 5 parts, safflower, 5 parts of cordate houttuynias, 12 parts of the Radixs Astragali, 10 parts of rhizoma cyperis, 9 parts of great burdock achenes, 12 parts of ginkgo leaves,12 parts of Chinese mahonias, 12 parts of tribulus terrestrises, 15 parts of lucid asparagus, 12 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 3 pharmaceutical composition of the present invention and preparation technology
The weight portion of traditional Chinese medicinal components: 11 parts of Bupleurum Chineses, 7 parts of schizonepeta, 7 parts, cultivated land, 4 parts of folium isatidis, 11 parts of peppermints,11 parts of Ligusticum wallichiis, 4 parts, safflower, 4 parts of cordate houttuynias, 11 parts of the Radixs Astragali, 9 parts of rhizoma cyperis, 8 parts of great burdock achenes, 11 parts of ginkgo leaves,11 parts of Chinese mahonias, 11 parts of tribulus terrestrises, 13 parts of lucid asparagus, 10 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 4 pharmaceutical composition of the present invention and preparation technology
The weight portion of traditional Chinese medicinal components: 10 parts of Bupleurum Chineses, 5 parts of schizonepeta, 6 parts, cultivated land, 3 parts of folium isatidis, 10 parts of peppermints,10 parts of Ligusticum wallichiis, 3 parts, safflower, 3 parts of cordate houttuynias, 10 parts of the Radixs Astragali, 8 parts of rhizoma cyperis, 6 parts of great burdock achenes, 10 parts of ginkgo leaves,10 parts of Chinese mahonias, 10 parts of tribulus terrestrises, 12 parts of lucid asparagus, 9 parts, Radix Glycyrrhizae, 5 parts, Poria cocos, 13 parts of Radix Angelicae Sinensis
Preparation method is with embodiment 1.
Embodiment 5 pharmaceutical composition of the present invention and preparation technology
The weight portion of traditional Chinese medicinal components: 12 parts of Bupleurum Chineses, 8 parts of schizonepeta, 9 parts, cultivated land, 5 parts of folium isatidis, 12 parts of peppermints,12 parts of Ligusticum wallichiis, 5 parts, safflower, 5 parts of cordate houttuynias, 12 parts of the Radixs Astragali, 10 parts of rhizoma cyperis, 9 parts of great burdock achenes, 12 parts of ginkgo leaves,12 parts of Chinese mahonias, 12 parts of tribulus terrestrises, 15 parts of lucid asparagus, 12 parts, Radix Glycyrrhizae, 8 parts, Poria cocos, 12 parts of Radix Angelicae Sinensis.
Preparation method is with embodiment 1.
Embodiment 6 pharmaceutical composition of the present invention and preparation technology
The weight portion of traditional Chinese medicinal components: 11 parts of Bupleurum Chineses, 7 parts of schizonepeta, 7 parts, cultivated land, 4 parts of folium isatidis, 11 parts of peppermints,11 parts of Ligusticum wallichiis, 4 parts, safflower, 4 parts of cordate houttuynias, 11 parts of the Radixs Astragali, 9 parts of rhizoma cyperis, 8 parts of great burdock achenes, 11 parts of ginkgo leaves,Chinese mahonia 11,11 parts of tribulus terrestrises, 13 parts of lucid asparagus, 10 parts, Radix Glycyrrhizae, 6 parts, Poria cocos, 15 parts of Radix Angelicae Sinensis.
Preparation method is with embodiment 1.
(2) drug effect embodiment part
The antiinflammatory action of embodiment 7 pharmaceutical composition paraxylene of the present invention induced mice inflammatory model
Hydrocortisone has stronger anti-inflammatory activity, be artificial synthetic be also naturally occurring glucocorticoid, hydrogenation canPine enters after cell, activates cytoplasmic receptor, enters nucleus after allosteric, is combined with DNA response element, causes that gene turnsInhibition or the induction of record, change the expression of inflammation GAP-associated protein GAP.
1, experimental technique:
40 KM mouse, male and female half and half, body weight 25-30 gram, is divided into four groups at random by body weight, i.e. model control group, combination groupDosage group in high dose group, composition, composition low dose group, positive controls, 10 every group, each administration group mouse is respectivelyGive following medicine:
Model control group: gavage gives the physiological saline of same volume;
Positive controls: gavage gives the hydrocortisone drug solution of 5mg/kg;
Composition high dose group: gavage gives 1000mg/kg embodiment 1 pharmaceutical composition, and pharmaceutical composition is by crude drug amount;
Dosage group in composition: gavage gives 200mg/kg embodiment 1 pharmaceutical composition, and pharmaceutical composition is by crude drug amount;
Composition low dose group: gavage gives 50mg/kg embodiment 1 pharmaceutical composition, and pharmaceutical composition is by crude drug amount;
Each administration group is administered once every day, successive administration 7d. After last administration, get dimethylbenzene 20 μ l, be applied to each mouse right ear. 30After minute, get and be respectively subject to reagent 0.03ml to be evenly applied to respectively mouse right ear, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures each group littleThe mouse left and right ear method of double differences. Ear method of double differences assay method: place cuts two ears along auricle baseline, uses 8mm card punch at the same position of left and right earLay auricle, weigh, the ear method of double differences=auris dextra sheet weight-left auricle weight. The ear method of double differences can be used as evaluates anti-inflammatory index.
2, experimental result:
Measure each experimental mice ear method of double differences and evaluate the antiphlogistic effects of each medication group medicine. Measurement result is in table 2.
The comparison of the each experimental mice ear of table 2 method of double differences
Group n The ear method of double differences (mg)
Model control group 10 8.23±1.14
Positive controls 10 6.26±1.52*
Composition high dose group 10 2.84±1.82**##
Dosage group in composition 10 4.48±1.50**#
Composition low dose group 10 5.98±1.21*
With model control group comparison,*P < 0.05; With model control group comparison,**P＜0.01；
With positive controls comparison,#P < 0.05; With positive controls comparison,##P＜0.01。
Result demonstration gives positive drug and pharmaceutical composition of the present invention all can be obtained significant antiphlogistic effects, wherein medicine of the present inventionThe antiphlogistic effects of composition high dose group and positive controls have utmost point significant difference, pharmaceutical composition low dose group and positive controlGroup has significant difference, and this shows that the high dose group of pharmaceutical composition of the present invention and the antiphlogistic effects of low dose group will significantly be better thanPositive controls.
The impact of embodiment 8 pharmaceutical composition of the present invention on mouse hot-plate analgesia
1 mouse hot plate pain model is made
Body weight 20g left and right female mice is placed on hot plate pain threshold detector, screens 90 of qualified ♀ mouse and (lick metapedes time < 5sOr > 30s throws aside, and for preventing that foot from scalding, also should establish deadline, is generally 60s), add diving of metapedes reaction with mouseThe volt phase is threshold of pain index, gets 72 jennies, is divided into 6 groups, 12/group, and on model group, Dobell, folium isatidisClear sheet group, pharmaceutical composition of the present invention (making by pharmaceutical composition prescription and preparation technology described in embodiment 1) low dose group,Middle dosage group and high dose group. Each group is gastric infusion, and 1 times/day, dosage is as shown in table 10, successive administration 14dAfter, the time that after mensuration last medicine, 60min, 120min add foot reaction.
2 pharmaceutical compositions of the present invention are on licking the impact of foot response latency in the experiment of mouse hot-plate analgesia
Mouse licks foot response latency time showing, with model group comparison, and after administration after 1h and 2h, drug regimen of the present inventionAll be greater than model group the incubation period that the mouse of each administration group of thing is added foot reaction, has dose-dependence, and high dose groupIncubation period be significantly greater than model group (P < 0.05). Illustrate this pharmaceutical composition of the present invention can extend mouse to hot plate stimulateAdd the sufficient response latency, have certain analgesic activity. Under same experiment condition, positive control drug Dobell group (P < 0.05)With folium isatidis supernatant sheet group (1h, P < 0.05; 2h, P < 0.01) also extend the incubation period that mouse is added foot reaction, have oneFixed analgesic activity, but its analgesic effect and model group there was no significant difference. The results are shown in Table 3.
Table 3 mouse licks foot response latency timetable
Group Dosage (mg/kg) 1h(s) 2h(s)
Model group - 23.5±4.9 24.5±6.3
Hydrocortisone 150 25.5±9.9 26.1±7.9
Composition low dose group 50 28.5±7.9* 31.1±7.8*
Dosage group in composition 200 29.4±7.1* 32.4±10.4*
Composition high dose group 1000 32.6±8.4* 34.5±7.8**
Note: with model group comparison, * P < 0.05, * * P < 0.01.

Claims (7)

1. a pharmaceutical composition for the treatment of chronic tonsillitis, is characterized in that, its raw material by following weight portion is made: northRadix bupleuri 10-12 part, schizonepeta 5-8 part, cultivated land 6-9 part, folium isatidis 3-5 part, peppermint 10-12 part, Ligusticum wallichii 10-12 part,Safflower 3-5 part, cordate houttuynia 3-5 part, Radix Astragali 10-12 part, rhizoma cyperi 8-10 part, great burdock achene 6-9 part, ginkgo leaf 10-12 part,Chinese mahonia 10-12 part, tribulus terrestris 10-12 part, lucid asparagus 12-15 part, Radix Glycyrrhizae 9-12 part.
2. pharmaceutical composition as claimed in claim 1, is characterized in that, described pharmaceutical composition also contains Poria cocos 5-8 partWith Radix Angelicae Sinensis 12-15 part.
3. pharmaceutical composition as claimed in claim 1, is characterized in that, described pharmaceutical composition is former by following weight portionMaterial is made: 11 parts of Bupleurum Chineses, 7 parts of schizonepeta, 7 parts, cultivated land, 4 parts of folium isatidis, 11 parts of peppermints, 11 parts of Ligusticum wallichiis, safflower4 parts, 4 parts of cordate houttuynias, 11 parts of the Radixs Astragali, 9 parts of rhizoma cyperis, 8 parts of great burdock achenes, 11 parts of ginkgo leaves, 11 parts of Chinese mahonias,11 parts of tribulus terrestrises, 13 parts of lucid asparagus, 10 parts, Radix Glycyrrhizae.
4. pharmaceutical composition as claimed in claim 4, is characterized in that, described pharmaceutical composition also contains Poria cocos 5-8 partWith Radix Angelicae Sinensis 12-15 part.
5. pharmaceutical composition as claimed in claim 1 or 2, is characterized in that, described pharmaceutical composition be powder, mixture,Tablet or capsule.
6. pharmaceutical composition as claimed in claim 1 or 2, is characterized in that, preparation method's bag of described pharmaceutical compositionContaining following step: get recipe quantity Chinese medicine and be broken into meal, according to 4～9 times of meal gross weight add volumetric concentration be 40%～95% ethanolic solution, refluxing extraction three times, return time is 2～5h, filters, filtrate recycling ethanol, cold filtration, usesWater washing, obtains Chinese medical concrete after being dried; Those skilled in the art can this preparation method technical prepare normal clinicallyUse Chinese medicine formulation, as tablet, capsule etc.
7. the purposes of the pharmaceutical composition described in claim 1 or 2 in preparation treatment chronic tonsillitis medicine.
CN201610038270.0A 2016-01-20 2016-01-20 Pharmaceutical composition for treating chronic tonsillitis Withdrawn CN105596690A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610038270.0A CN105596690A (en) 2016-01-20 2016-01-20 Pharmaceutical composition for treating chronic tonsillitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610038270.0A CN105596690A (en) 2016-01-20 2016-01-20 Pharmaceutical composition for treating chronic tonsillitis

Publications (1)

Publication Number Publication Date
CN105596690A true CN105596690A (en) 2016-05-25

Family

ID=55977415

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610038270.0A Withdrawn CN105596690A (en) 2016-01-20 2016-01-20 Pharmaceutical composition for treating chronic tonsillitis

Country Status (1)

Country Link
CN (1) CN105596690A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104547484A (en) * 2014-12-18 2015-04-29 蓝春秀 Traditional Chinese medicine component for treating chronic tonsillitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104547484A (en) * 2014-12-18 2015-04-29 蓝春秀 Traditional Chinese medicine component for treating chronic tonsillitis

Similar Documents

Publication Publication Date Title
CN104027529A (en) Traditional Chinese medicine composition for regulating blood lipids, blood pressure and blood glucose and preparation method thereof
CN103099948A (en) Pharmaceutical composition for treating pharyngitis and preparation method
CN102631579B (en) Oral Chinese herbal preparation for treating post-traumatic brain syndrome
CN103432545A (en) Medicament for allaying fever of child and preparation method thereof
CN103495048A (en) Traditional Chinese medicine composition for treating children&#39;s aphthous stomatitis
CN104056177A (en) Traditional Chinese medicine composition for treating otitis media
CN105456818A (en) Traditional Chinese medicine composition containing folium artemisiae argyi and being capable of treating insomnia and preparation method of traditional Chinese medicine composition
CN104435567A (en) Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout
CN103585545B (en) Traditional Chinese medicine composition for treating otitis media
CN103861031A (en) Traditional Chinese medicine for treating chronic superficial gastritis
CN103845592A (en) Traditional Chinese medicine for treating cervical lymph node tuberculosis
CN103041320B (en) Traditional Chinese medicine composition for treating cervical spondylosis and preparation method thereof
CN105596690A (en) Pharmaceutical composition for treating chronic tonsillitis
CN100496572C (en) Chinese traditional medicine composition and method of making the same
CN104623376A (en) Medicament for treating prosopalgia
CN104173830A (en) Medicament for reconciling interior syndromes and relieving exterior syndromes for high fever of cold in winter and preparation method thereof
CN104435545A (en) Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning
CN103566219A (en) Traditional Chinese medicine composition for treating cold
CN103861041A (en) Traditional Chinese medicinal composition for treating acute and chronic rhinitis and preparation method thereof
CN103520475B (en) A kind of pharmaceutical composition being used for the treatment of skin pruritus
CN104324212A (en) Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof
CN105362999A (en) Traditional Chinese medicine preparation for preventing and treating infantile repeated cold and preparation method thereof
CN102416147B (en) Medicinal composition for treating mania of patients abstained from drugs
CN102274418A (en) Medicinal powder for preventing and treating anemofrigid cold of livestock and poultry
CN104435629B (en) A kind of recurrent oral ulceration for the treatment of merges Chinese medicine of laryngopharynx swelling and pain and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160525